20452 Federal Register / Vol. 87, No. 67 / Thursday, April 7, 2022 / Notices 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 1, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–07377 Filed 4–6–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Office of the Secretary; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Muscular Dystrophy 

Coordinating Committee (MDCC). 

The meeting will be open to the 

public. Individuals who plan to 

participate and need special assistance, 

such as sign language interpretation or 

other reasonable accommodations, 

should notify the Contact Person listed 

below in advance of the meeting. 

Name of Committee: Muscular Dystrophy 

Coordinating Committee. 

Date: May 9, 2022. 

Time: 1:00 p.m. to 5:00 p.m. EST. 

Agenda: The purpose of this meeting is to 

bring together committee members, 

representing government agencies, patient 

advocacy groups, other voluntary health 

organizations, and patients and their families 

to update one another on progress relevant to 

the Action Plan for the Muscular Dystrophies 

and to coordinate activities and discuss gaps 

and opportunities leading to better 

understanding of the muscular dystrophies, 

advances in treatments, and improvements in 

patients’ and their families’ lives. The agenda 

for this meeting is available on the MDCC 

website: https://www.mdcc.nih.gov/. 

Registration: To register, please go to: 

https://roseliassociates.zoomgov.com/ 

webinar/register/WN_- 

4KzEwSKRniqdjFz12Zh0A. 

Webcast Live: https://videocast.nih.gov/. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Glen Nuckolls, Ph.D., 

Program Director, National Institute of 

Neurological Disorders and Stroke (NINDS), 

NIH, 6001 Executive Blvd., Rm 2203, 

Bethesda, MD 20892, 301–496–5876, MDCC@

nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

More information can be found on the 

Muscular Dystrophy Coordinating Committee 

home page: https://mdcc.nih.gov/. 

Dated: April 1, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–07380 Filed 4–6–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications 

and/or contract proposals and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications and/or contract proposals, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; High 

Priority HIV and Substance Use Research 

(R01 Clinical Trial Optional). 

Date: May 3, 2022. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–5843, trinh.tran@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Respiratory Safety Evaluations of Potential 

Medications for Opioid Overdose (8958). 

Date: May 4, 2022. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Sindhu Kizhakke 

Madathil, Ph.D., Scientific Review Officer, 

Scientific Review Branch, National Institute 

on Drug Abuse, NIH, 301 North Stonestreet 

Avenue, MSC 6021, Bethesda, MD 20892, 

(301) 827–5702, sindhu.kizhakkemadathil@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: April 1, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–07388 Filed 4–6–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; Drug 

Repositioning and Combination Therapy for 

AD. 

Date: May 6, 2022. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Alexander Parsadanian, 

Ph.D., Scientific Review Officer National, 

Institute on Aging, Gateway Building 2C/212, 

7201 Wisconsin Avenue, Bethesda, MD 

20892, 301–496–9666, parsadaniana@

nia.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: April 1, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–07385 Filed 4–6–22; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES